Bionano Genomics opened higher at $1.12, compared with its previous close of $1.10. In the last trading session, the stock traded between $0.97 and $1.12. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Bionano Genomics is now worth
$ 0.03
Resulting in a loss of
$ 99.97 (99.97%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.07 (-6.18%)
Day High
$1.12
Day Low
$0.97
Day Open
$1.12
Prev Close
$1.10
Volume
8,27,906
1W Return
-13.64%
1M Return
-22.70%
3M Return
-13.20%
6M Return
-18.74%
1Y Return
-36.30%
Fundamentals
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
0.44
PEG Ratio
-
ROE
-59.14%
ROCE
-61.88%
EPS (TTM)
$-0.63
Investment Returns
1 Week
-13.64%
1 Month
-22.70%
3 Months
-13.20%
6 Months
-18.74%
9 Months
-9.47%
Financials
Quarterly
All values in $ Mn
6.5
Mar 25
6.7
Jun 25
7.4
Sep 25
8.0
Dec 25
6.7
Mar 26
8.2
Jun 26
Updates
11Nov
Bionano Genomics Q3FY26 Results: Loss per share widens, revenue misses
Loss per share narrowed 66.04% YoY to $(0.54), but missed analyst estimates by 8%. Revenue rose 12.34% YoY to $8.276 million, missing consensus by 1.98%. Record flow cell sales of 9,870 units drove consumable revenue up 24%. Full-year 2026 revenue guidance reiterated at $31-33 million; EBITDA neutrality targeted for end-2027.
2 days ago
14Sep
Bionano studies show OGM detects hidden genomic risks in MDS and AML
Three peer-reviewed studies confirm OGM detects structural genomic alterations in MDS, AML, and t-MN missed by standard karyotyping. OGM maintained 100% interpretability in a Spanish cohort where conventional banding failed in eight cases due to lack of dividing cells. Chromoanagenesis identified in 15.9% of MDS cases linked to median overall survival of 9.9 months versus not reached for non-CAG subjects. OGM findings shifted 16.7% of t-MN and up to 12.8% of younger-onset MDS subjects into higher-risk prognostic categories.
1mo ago
11Aug
Bionano Genomics Q2 Results: Revenue rises 21% to $8.2 million
Bionano Genomics posted Q2 2026 revenue of $8.2 million, up 21% YoY, fueled by a 31% jump in consumable sales. The company retired all secured convertible debentures, removing asset liens. Full-year 2026 revenue guidance is set at $31–$33 million.
Bionano Genomics forecasts Q3 sales of $8.200M-$8.600M, hovering around the $8.575M analyst estimate. The guidance suggests a stable outlook with limited upside potential beyond the upper bound, requiring strong execution to exceed consensus.
3mo ago
11Aug
Bionano Genomics raises FY26 sales guidance range
Bionano Genomics Inc. upgrades FY2026 sales guidance to $31.000M-$33.000M, up from $30.000M-$33.000M. The new outlook beats the $32.137M consensus estimate, indicating improved revenue visibility and reduced downside risk for the fiscal year.
